Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.98 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL27598945 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29461927 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8378216 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL27706849 | 0.99 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29846325 | 0.99 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL14109970 | 0.99 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL147362 | 0.99 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13154676 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13696339 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5577 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | claimed |
| US-12285488-B2 | Oral dosage form containing theobromine-free cocoa | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-04-29 | — | — | US | claimed |
| CN-119894893-A | Sulfone substituted pyrido [3,4-D ] pyrimidine derivatives for the treatment of cancer | 拜耳公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2025021997-A1 | NEW MAP4K1 INHIBITORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-01-30 | — | — | WO | claimed |
| WO-2025016899-A1 | SPIROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-23 | — | — | WO | claimed |
| EP-4476221-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-12-18 | — | — | EP | claimed |
| CN-117461602-B | Construction method of morphine addiction animal model | 六合熙诚(北京)信息科技有限公司 | 2024-10-25 | — | — | CN | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| WO-1994003161-A1 | CONTROLLED RELEASE MORPHINE PREPARATION | GACELL LABORATORIES AB (SE) | 1994-02-17 | — | — | WO | claimed |
| US-5240932-A | In mixture with terpene and an oil | Morimoto, Yasunori (JP) | 1993-08-31 | — | — | US | claimed |
| US-5202128-A | Oral administering | F. H. FAULDING & CO. LIMITED (AU) | 1993-04-13 | — | — | US | claimed |
| US-5102887-A | Method for reducing emesis and nausea induced by the administration of an emesis causing agent | ARCH DEVELOPMENT CORPORATION (US) | 1992-04-07 | — | — | US | claimed |
| EP-0476205-A1 | Sustained release morphine preparation for rectal administration | TORII & CO., LTD. (JP) | 1992-03-25 | — | — | EP | claimed |
| US-5061492-A | biodegeadeable polymer matrix is copolymer of gylcolic acid a nd lactic acid | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-29 | — | — | US | claimed |
| EP-0430414-A1 | Morphine hydrochloride preparation for rectal administration | TORII & CO., LTD. (JP) | 1991-06-05 | — | — | EP | claimed |
| US-4711782-A | Prolonged release microcapsules and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-12-08 | — | — | US | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| US-4389404-A | POLYVINYLPYRROLIDONE, MORPHINE HYDROCHLORIDE | ZHOROV VLADIMOR I (SU) | 1983-06-21 | — | — | US | claimed |